Stargardt Disease - Pipeline Insight, 2021
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Stargardt Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Stargardt Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Stargardt Disease: Overview
Stargardt disease is an inherited disorder of the retina — the tissue at the back of the eye that senses light. The disease typically causes vision loss during childhood or adolescence, although in some forms, vision loss may not be noticed until later in adulthood. It is rare for people with the disease to become completely blind. For most people, vision loss progresses slowly over time to 20/200 or worse. (Normal vision is 20/20). The most common symptom of Stargardt disease is variable, often slow loss of central vision in both eyes. People with the disease might notice gray, black, or hazy spots in the center of their vision, or that it takes longer than usual for their eyes to adjust when moving from light to dark environments. Their eyes may be more sensitive to bright light. Some people also develop color blindness later in the disease.
'Stargardt Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stargardt Disease pipeline landscape is provided which includes the disease overview and Stargardt Disease treatment guidelines. The assessment part of the report embraces, in depth Stargardt Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stargardt Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Stargardt Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Stargardt Disease Emerging Drugs
Further product details are provided in the report……..
Stargardt Disease: Therapeutic Assessment
This segment of the report provides insights about the different Stargardt Disease drugs segregated based on following parameters that define the scope of the report, such as:
Stargardt Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stargardt Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stargardt Disease drugs.
Stargardt Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Stargardt Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Stargardt Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Stargardt Disease: Overview
Stargardt disease is an inherited disorder of the retina — the tissue at the back of the eye that senses light. The disease typically causes vision loss during childhood or adolescence, although in some forms, vision loss may not be noticed until later in adulthood. It is rare for people with the disease to become completely blind. For most people, vision loss progresses slowly over time to 20/200 or worse. (Normal vision is 20/20). The most common symptom of Stargardt disease is variable, often slow loss of central vision in both eyes. People with the disease might notice gray, black, or hazy spots in the center of their vision, or that it takes longer than usual for their eyes to adjust when moving from light to dark environments. Their eyes may be more sensitive to bright light. Some people also develop color blindness later in the disease.
'Stargardt Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Stargardt Disease pipeline landscape is provided which includes the disease overview and Stargardt Disease treatment guidelines. The assessment part of the report embraces, in depth Stargardt Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stargardt Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Stargardt Disease R&D. The therapies under development are focused on novel approaches to treat/improve Stargardt Disease.
This segment of the Stargardt Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Stargardt Disease Emerging Drugs
- Emixustat hydrochloride: Kubota Vision
- ALK-001: Alkeus Pharmaceuticals
Further product details are provided in the report……..
Stargardt Disease: Therapeutic Assessment
This segment of the report provides insights about the different Stargardt Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Stargardt Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Stargardt Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Stargardt Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Stargardt Disease drugs.
Stargardt Disease Report Insights
- Stargardt Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Stargardt Disease drugs?
- How many Stargardt Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Stargardt Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Stargardt Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Stargardt Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kubota Vision
- Alkeus Pharmaceuticals
- IVERIC bio
- Generation Bio
- Nanoscope Therapeutics
- Stargazer Pharmaceuticals, Inc.
- Astellas Pharma
- Spark Therapeutics
- Katairo
- Vitrisa Therapeutics
- Biophytis
- Belite Bio
- Biogen
- ReVision Therapeutics
- Applied Genetic Technologies Corporation
- Beam Therapeutics
- Curative Biotechnology
- ProQR Therapeutics
- 4P-Pharma
- Coave Therapeutics
- Abeona Therapeutics
- Connectyx
- Emixustat hydrochloride
- ALK-001
- Avacincaptad pegol
- MCO 010
- STG-001
- MA09-hRPE
- Soraprazan
- Macuneos
- BPN-14967
- NSR-BEST1
- CVZ 002
- AAV2/5-GRK1-hRPGRco
- Metformin
- 4P-020
- CTx-ABCA4
- REV-0100
Introduction
Executive Summary
Stargardt Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Emixustat hydrochloride: Kubota Vision
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALK-001: Alkeus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
BPN-14967: Belite Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
REV-0100: ReVision Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Stargardt Disease Key Companies
Stargardt Disease Key Products
Stargardt Disease- Unmet Needs
Stargardt Disease- Market Drivers and Barriers
Stargardt Disease- Future Perspectives and Conclusion
Stargardt Disease Analyst Views
Stargardt Disease Key Companies
Appendix
Executive Summary
Stargardt Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Emixustat hydrochloride: Kubota Vision
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
ALK-001: Alkeus Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
BPN-14967: Belite Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
REV-0100: ReVision Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Stargardt Disease Key Companies
Stargardt Disease Key Products
Stargardt Disease- Unmet Needs
Stargardt Disease- Market Drivers and Barriers
Stargardt Disease- Future Perspectives and Conclusion
Stargardt Disease Analyst Views
Stargardt Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Stargardt Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Stargardt Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Stargardt Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Stargardt Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
